Generic Duexis Availability

Last updated on Jun 11, 2025.

Duexis is a brand name of famotidine/ibuprofen, approved by the FDA in the following formulation(s):

DUEXIS (famotidine; ibuprofen - tablet;oral)

• Manufacturer: HORIZON
  Approval date: April 23, 2011
  Strength(s): 26.6MG;800MG (discontinued) ^{[RLD] [AB]}

All of the above formulations have been discontinued.

Is there a generic version of Duexis available?

A generic version of Duexis has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Duexis and have been approved by the FDA:

IBUPROFEN AND FAMOTIDINE (famotidine; ibuprofen tablet;oral)

• Manufacturer: ALKEM LABS LTD
  Approval date: August 3, 2021
  Strength(s): 26.6MG;800MG ^[AB]
• Manufacturer: ASCENT PHARMS INC
  Approval date: March 15, 2023
  Strength(s): 26.6MG;800MG ^[AB]
• Manufacturer: ENDO OPERATIONS
  Approval date: March 22, 2024
  Strength(s): 26.6MG;800MG ^[AB]
• Manufacturer: TEVA PHARMS USA
  Approval date: October 29, 2021
  Strength(s): 26.6MG;800MG ^[AB]
• Manufacturer: ZYDUS PHARMS
  Approval date: February 20, 2025
  Strength(s): 26.6MG;800MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Duexis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Methods and medicaments for administration of ibuprofen
  Patent 8,067,451
  Issued: November 29, 2011
  Inventor(s): Tidmarsh; George et al.
  Assignee(s): Horizon Pharma USA, Inc. (Northbrook, IL)
  

  A method for administration of ibuprofen to a subject in need of ibuprofen treatment is provided, in which an oral dosage form comprising a therapeutically effective amount of ibuprofen and a therapeutically effective amount of famotidine is administered three times per day.

  Patent expiration dates:

  • July 18, 2026
    
    ✓ 
    Patent use: RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS
    ✓ 
    Drug product
• Stable compositions of famotidine and ibuprofen
  Patent 8,309,127
  Issued: November 13, 2012
  Inventor(s): Xu Jerry & Tidmarsh George F.
  Assignee(s): Horizon Pharma USA, Inc.
  

  Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.

  Patent expiration dates:

  • July 18, 2026
    
    ✓ 
    Drug product
• Stable compositions of famotidine and ibuprofen
  Patent 8,318,202
  Issued: November 27, 2012
  Inventor(s): Xu Jerry & Tidmarsh George F.
  Assignee(s): Horizon Pharma USA, Inc.
  

  Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.

  Patent expiration dates:

  • July 18, 2026
    
    ✓ 
    Drug product
• Stable compositions of famotidine and ibuprofen
  Patent 8,449,910
  Issued: May 28, 2013
  Inventor(s): Xu Jerry & Tidmarsh George F.
  Assignee(s): Horizon Pharma USA, Inc.
  

  Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.

  Patent expiration dates:

  • July 18, 2026
    
    ✓ 
    Drug product
• Stable compositions of famotidine and ibuprofen
  Patent 8,501,228
  Issued: August 6, 2013
  Inventor(s): Xu Jerry & Tidmarsh George F.
  Assignee(s): Horizon Pharma USA, Inc.
  

  Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.

  Patent expiration dates:

  • July 18, 2026
    
    ✓ 
    Patent use: RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer